List of Excipients in Branded Drug CARIMUNE

« Back to Dashboard

CARIMUNE Excipient Strategy and Commercial Opportunities in Intravenous Immunoglobulin

Last updated: October 17, 2026

Carimune NF is a lyophilized intravenous immune globulin human product associated with CSL Behring. Its core excipient system is sucrose with sodium chloride, reconstituted with Sterile Water for Injection. The formulation provides a clear development opportunity for sucrose-free renal-risk reduction, ready-to-use liquid delivery, low-IgA positioning, lower infusion volume, and more convenient outpatient administration. Carimune is a biologic, so its market protection is driven primarily by manufacturing complexity, donor-plasma supply, regulatory approvals, trademarks, and clinical differentiation rather than conventional small-molecule patent exclusivity.

What is Carimune and how is it formulated?

Carimune NF is a nanofiltered, lyophilized human immunoglobulin G product administered intravenously. The labeled presentations contain 3 g, 6 g, or 12 g of human immunoglobulin G, typically reconstituted to approximately 50 mL, 100 mL, or 200 mL, respectively.[1]

What excipients does Carimune contain?

The principal formulation components are:

Component	Role in Carimune formulation	Commercial significance
Human IgG	Active biological substance	Requires plasma sourcing, fractionation, viral clearance, and potency control
Sucrose	Stabilizer and lyoprotectant	Supports protein stability during freeze-drying but carries renal-safety concerns
Sodium chloride	Tonicity adjustment	Influences infusion tolerability and sodium load
Sterile Water for Injection	Reconstitution vehicle	Creates handling steps and increases preparation time
Trace IgA	Process-related protein component	Relevant to hypersensitivity and low-IgA product positioning

Carimune contains no antimicrobial preservative. The product label identifies sucrose as a stabilizer and warns of acute renal dysfunction, acute renal failure, osmotic nephrosis, and death in susceptible patients receiving sucrose-containing intravenous immune globulin products.[1]

Why does the sucrose excipient matter?

Sucrose has historically provided effective stabilization for lyophilized IgG. Its commercial disadvantage is the renal-risk profile associated with some sucrose-containing immune globulin products. The label identifies patients with pre-existing renal insufficiency, diabetes mellitus, advanced age, volume depletion, paraproteinemia, sepsis, or nephrotoxic-drug exposure as higher-risk populations.[1]

A sucrose-free competitor can therefore differentiate on renal-risk management, although the clinical claim must be supported by formulation, labeling, pharmacovigilance, and comparative evidence. Removing sucrose does not eliminate all renal risk associated with intravenous immunoglobulin. Product concentration, infusion rate, osmolality, sodium content, patient comorbidities, and aggregate protein exposure remain relevant.

What formulation patents protect Carimune?

Publicly available product information identifies Carimune as a legacy biologic formulation rather than a product with a prominent, commercially controlling formulation-patent estate. No active Carimune-specific formulation patent should be assumed without a current patent-family and legal-status review.

Is Carimune listed in the Orange Book?

Carimune is a biologic product licensed under the Public Health Service Act. The FDA Orange Book is principally organized around approved drug products submitted under the Federal Food, Drug, and Cosmetic Act. Biologic reference-product information is generally evaluated through the FDA Purple Book rather than conventional Orange Book patent listings.[2,3]

As a result, an Orange Book Paragraph IV strategy is not the normal route for challenging Carimune. The relevant pathway is a biologics license application or, where statutory requirements are met, an abbreviated approval pathway under section 351(k) of the Public Health Service Act.

What intellectual property protects a replacement product?

The strongest protectable assets for a Carimune successor or competitor are likely to involve:

• IgG purification and fractionation processes.
• Viral inactivation and nanofiltration conditions.
• Low-IgA purification methods.
• Protein concentration and aggregation control.
• Lyophilization cycles and cake structure.
• Reconstitution time and stability.
• Sucrose-free stabilization systems.
• Ready-to-use liquid formulations.
• Container-closure systems.
• Infusion-device compatibility.
• Methods for reducing renal complications or infusion reactions.

Manufacturing patents can be more commercially important than composition-of-matter patents because polyclonal IgG products are difficult to reproduce through a simple active-ingredient substitution.

What is the FDA regulatory status of Carimune?

Carimune NF is an FDA-licensed human immune globulin intravenous product. Public labeling identifies indications including primary immunodeficiency, immune thrombocytopenic purpura, and chronic inflammatory demyelinating polyneuropathy.[1]

Regulatory issue	Carimune position
Product type	Human immune globulin intravenous
Regulatory category	Biologic
Dosage form	Lyophilized powder for injection
Administration	Intravenous infusion
Key stabilizer	Sucrose
Preservative	None
Reconstitution	Sterile Water for Injection
Major safety issue	Renal dysfunction and thrombosis risk
Relevant reference source	FDA prescribing information and Purple Book framework

The commercial status of a legacy biologic can vary by presentation, distributor, manufacturing allocation, and temporary supply conditions. FDA licensing alone does not establish continuous commercial availability in every market or package size.

When does Carimune lose exclusivity?

Carimune does not have a conventional small-molecule exclusivity timeline that can be reduced to a single patent expiration date. Biologic market entry depends on several overlapping rights and operational barriers:

1. Patent expiration and enforceability.
2. Regulatory data and market exclusivity.
3. FDA approval pathway.
4. Reference-product designation.
5. Plasma collection capacity.
6. Fractionation and purification technology.
7. Viral-clearance validation.
8. Manufacturing scale and release testing.
9. Hospital and specialty-pharmacy contracting.

For a 351(k) biosimilar or interchangeable product, FDA approval requires extensive analytical, functional, pharmacokinetic, and immunogenicity evidence. Because intravenous immunoglobulin is a complex polyclonal mixture, demonstrating similarity presents different technical challenges from monoclonal antibodies with a defined molecular target.

What generic entry risks exist for Carimune?

Traditional generic substitution is unlikely to be the principal competitive threat. The more relevant risks are:

Biosimilar and follow-on immune globulin competition

A biosimilar developer would need to establish similarity to the reference product while controlling variability arising from donor pools, fractionation, IgG subclass distribution, aggregates, charge variants, and trace proteins. The product is not a single molecular entity. This increases development complexity and may reduce the probability of rapid market entry.

No broad assumption of automatic pharmacy substitution should be made. Interchangeability, state substitution rules, payer policy, and product-specific FDA determinations control substitution.

Therapeutic substitution

Carimune competes with other intravenous immune globulin products, including Privigen, Gamunex-C, Flebogamma DIF, Octagam, and Panzyga, depending on market and indication. These products can displace Carimune without being legally substitutable at the pharmacy level.

Route-of-administration substitution

Subcutaneous immune globulin products such as Hizentra, Cuvitru, and HyQvia can reduce reliance on intravenous administration in suitable patients, particularly in primary immunodeficiency maintenance therapy. This creates a larger commercial threat than a direct Carimune generic in some segments.

How does Carimune compare with competing immune globulin products?

Product	Manufacturer	General formulation positioning	Key competitive distinction
Carimune NF	CSL Behring	Lyophilized, sucrose-stabilized IVIG	Established legacy product; reconstitution required
Privigen	CSL Behring	Liquid, proline-stabilized IVIG	Ready-to-use formulation; sucrose-free positioning
Gamunex-C	Grifols	Liquid, glycine-stabilized IVIG	Broad IVIG and subcutaneous-use positioning
Panzyga	Octapharma	Liquid IVIG	Modern liquid presentation and broad hospital use
Octagam	Octapharma	Liquid IVIG	Alternative stabilization and supply platform
Hizentra	CSL Behring	Subcutaneous IgG	Home-based administration
HyQvia	Takeda	Facilitated subcutaneous IgG	Hyaluronidase-enabled large-volume subcutaneous delivery

The clearest formulation comparison is between Carimune's lyophilized sucrose system and modern liquid, sucrose-free products. Liquid systems eliminate reconstitution but require long-term control of aggregation, particulates, viscosity, oxidation, and container interaction.

What excipient strategies create commercial opportunities?

Sucrose-free stabilization

A sucrose-free formulation can target hospitals and prescribers concerned about renal risk. Candidate excipient classes include amino acids, polyols, surfactants, and buffered systems. Each creates tradeoffs involving protein aggregation, viscosity, osmolality, infusion tolerability, and container compatibility.

The strongest product profile would combine sucrose-free stabilization with low aggregate levels, low particulate burden, rapid infusion capability, and a clear renal-risk label.

Ready-to-use liquid presentation

Replacing Carimune's freeze-dried presentation with a stable liquid can reduce pharmacy preparation, reconstitution errors, nursing time, and waste. Commercial value is highest in high-throughput infusion centers and hospital pharmacies.

The development burden is substantial. A liquid IgG product must demonstrate stability through temperature excursions, transportation, container closure, repeated handling, and extended shelf life.

Low-IgA formulation

Low-IgA products target patients with prior reactions to immunoglobulin products or clinically significant anti-IgA antibodies. A low-IgA claim requires validated purification and consistent lot release. It can support premium positioning but narrows the addressable market.

Higher concentration and lower infusion volume

A 10% or higher-concentration product can reduce infusion volume relative to a 3%, 6%, or 12% reconstituted presentation, depending on the labeled dose and final concentration. Lower volume is valuable for patients at risk of fluid overload and for outpatient infusion centers with limited chair capacity.

Concentration increases viscosity and may affect infusion rates, device performance, and tolerability. The commercial proposition must therefore be linked to actual administration time rather than concentration alone.

Improved reconstitution

If a lyophilized format is retained, excipient and cake-engineering improvements can shorten reconstitution time, reduce foaming, and improve vial recovery. This is a lower-risk product strategy than developing a fully liquid formulation and may support incremental lifecycle management.

Subcutaneous conversion

A subcutaneous presentation can extend the product into home treatment and reduce dependence on infusion centers. The product would require new administration volumes, injection-site tolerability data, device compatibility, and clinical support infrastructure. This is a platform opportunity rather than a simple Carimune reformulation.

What manufacturing and IP barriers affect commercial entry?

The primary barriers are plasma supply and manufacturing execution. An entrant needs access to qualified donors, collection centers, fractionation capacity, viral-clearance systems, nanofiltration, aseptic filling, validated cold-chain logistics, and lot-release testing.

Important technical controls include:

• IgG purity and subclass distribution.
• Aggregate and fragment content.
• Antibody potency against relevant antigens.
• IgA and other trace-protein levels.
• Viral and prion safety.
• Endotoxin and particulate limits.
• pH, osmolality, and viscosity.
• Stability after reconstitution.
• Container-closure integrity.

A patent strategy should protect the formulation, process parameters, analytical methods, device integration, and therapeutic use claims as separate families. Freedom-to-operate analysis must cover competitor patents even when Carimune-specific patents have expired or are absent.

Which companies are challenging Carimune commercially?

The competitive field includes CSL Behring, Grifols, Octapharma, Takeda, Kedrion, and other plasma-derived-product manufacturers. Competition is based on supply reliability, hospital contracts, payer access, infusion time, adverse-event profile, clinical familiarity, and route of administration.

The closest commercial challenge comes from modern liquid IVIG products and subcutaneous immunoglobulin platforms, not from a conventional generic launch.

What litigation and settlement risks affect Carimune?

No specific, currently controlling Carimune patent litigation or Paragraph IV settlement should be inferred from the product label alone. Biologic disputes are more likely to involve manufacturing patents, biosimilar applications, trade secrets, regulatory exclusivity, trademark rights, or product-liability claims than a conventional small-molecule Paragraph IV case.

A commercial entrant should model:

• Patent litigation over purification and stabilization.
• FDA litigation involving biosimilar approval or interchangeability.
• Antitrust and contracting disputes involving plasma supply.
• Trade-secret disputes over fractionation and viral-clearance processes.
• Product-liability exposure related to thrombosis, renal injury, and hypersensitivity.

What revenue exposure is associated with Carimune?

Carimune-specific revenue is difficult to isolate from public company reporting because manufacturers generally report broader plasma-derived and immunoglobulin categories. The commercial opportunity is therefore best assessed by segment:

Segment	Revenue opportunity	Main value driver
Hospital IVIG	High	Reliable supply and lower preparation burden
Neurology and CIDP	High	Chronic dosing and infusion-center use
Primary immunodeficiency	Moderate to high	Long-term maintenance demand
ITP and acute use	Variable	Episodic treatment and hospital protocols
Subcutaneous immunoglobulin	High growth potential	Home administration and capacity relief
Low-IgA products	Niche premium	Clinical differentiation
Ready-to-use liquid IVIG	Broad	Operational efficiency

Key Takeaways

• Carimune NF uses sucrose as its principal stabilizing excipient and requires reconstitution before intravenous administration.
• The main formulation opportunity is a sucrose-free, ready-to-use liquid product with lower renal-risk positioning.
• Carimune is a biologic, so Orange Book Paragraph IV litigation is not the primary market-entry framework.
• Direct substitution risk is lower than therapeutic substitution from modern IVIG and subcutaneous immunoglobulin products.
• Manufacturing capability, plasma supply, viral clearance, and lot consistency are major barriers to entry.
• Strong IP opportunities exist in stabilization, low-IgA purification, liquid formulations, lyophilization, analytical controls, and delivery systems.
• A competitive product should quantify administration-time reduction, infusion-volume reduction, renal-risk positioning, and supply reliability.

FAQs About Carimune Excipients and Commercial Strategy

Is Carimune sucrose-free?

No. Carimune NF is stabilized with sucrose, which is associated with labeled renal-risk warnings for susceptible patients.[1]

Can Carimune be reformulated as a liquid product?

Yes, but the reformulation would require new stability, packaging, manufacturing, and regulatory support. Liquid IgG products face aggregation, viscosity, particulate, and container-compatibility challenges.

Does Carimune have an Orange Book patent listing?

Carimune is a biologic product, and its principal regulatory reference framework is the FDA biologics system and Purple Book rather than conventional Orange Book patent listing practice.[2,3]

Is there a generic version of Carimune?

A conventional generic is not the expected pathway. A competing product would more likely require a biologics license application or a qualifying 351(k) biosimilar application.

What is the strongest commercial replacement strategy for Carimune?

The strongest strategy combines sucrose-free stabilization, ready-to-use liquid delivery, lower infusion volume, reliable supply, and a differentiated low-IgA or renal-risk profile.

References

1. U.S. Food and Drug Administration. (2016). Carimune NF: Immune globulin intravenous (human), nanofiltered prescribing information. CSL Behring LLC.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.

3. U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. FDA.